Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02202590 · ClinicalTrials.gov registry record · NA

Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus

A NA study of Eosinophilic Esophagitis, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
96
Enrollment target
1
Study location

NCT02202590: Active NA study of Eosinophilic Esophagitis, sponsored by Massachusetts General Hospital.

NCT02202590 is a NA study of Eosinophilic Esophagitis that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 96 participants, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02202590, a NA study of Eosinophilic Esophagitis, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.

Primary Outcome

An investigator will qualitatively assess the the Feasibility of SECM Capsule and Imaging in EoE participant versus Healthy Controls. He will assess the quality of the recorded images and movies obtained with each exam after the imaging is completed. The images obtained by the SECM Capsule will be compared to the images obtained by clinical endoscopy if available.

Conditions Studied

Interventions

  • DEVICE SECM Capsule

Study Locations (1)

Massachusetts

  • Massachusetts General hospital - Boston

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2013-10
Est. Completion 2028-12
Phase NA
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT02202590 still lists

NCT02202590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 862-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which SECM Capsule is the first listed.

NCT02202590 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02202590 about?

NCT02202590 is a clinical study titled "Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus". The goal of this study is to test the feasibility and the tolerability of a tethered spectrally encoded confocal microscopy (SECM) capsule and to use it to image the esophagus.

What is the current status of trial NCT02202590?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2013-10. Estimated completion is 2028-12.

What conditions does trial NCT02202590 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis.

What interventions are being tested in trial NCT02202590?

The interventions under investigation include: SECM Capsule (DEVICE).

Who is sponsoring clinical trial NCT02202590?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02202590 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02202590's enrollment target sits among peer trials

96 20th of 44 higher than 25 of 44 other Eosinophilic Esophagitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02202590, the US trial registry maintained by the National Library of Medicine. NCT02202590 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.